Top

Published in:

01-04-2016 | Original Article

Virus-inhibiting activity of dihydroquercetin, a flavonoid from Larix sibirica, against coxsackievirus B4 in a model of viral pancreatitis

Authors: Anastasia V. Galochkina, Vadim B. Anikin, Vasily A. Babkin, Liudmila A. Ostrouhova, Vladimir V. Zarubaev

Published in: Archives of Virology | Issue 4/2016

Abstract

Members of the family Picornaviridae, in particular, enteroviruses, represent a serious threat to human health. They are responsible for numerous pathologies ranging from mild disease to fatal outcome. Due to the limited number of safe and effective antivirals against enteroviruses, there is a need for search and development of novel drugs with various mechanisms of activity against enteroviruses-induced pathologies. We studied the effect of dihydroquercetin (DHQ), a flavonoid from larch wood, on the course of pancreatitis of white mice caused by coxsackievirus B4 (CVB4). DHQ was applied intraperitoneally at doses of 75 or 150 mg/kg/day once a day for 5 days postinfection (p.i.) starting on day 1 p.i., and its effect was compared to that of the reference compound ribavirin. The application of DHQ resulted in a dose-dependent decrease in the virus titer in pancreatic tissue, reaching, at the highest dose, 2.4 logs on day 5 p.i. Also, the application of DHQ led to restoration of antioxidant activity of pancreatic tissue that was impaired in the course of pancreatitis. Morphologically, pancreatic tissue of DHQ-treated animals demonstrated less infiltration with inflammatory cells and no signs of tissue destruction compared to placebo-treated mice. Both ribavirin- and DHQ-treated animals developed fewer foci of pancreatic inflammation per mouse, and these foci contained fewer infiltrating cells than those in placebo-treated mice. The effect of DHQ was comparable to or exceeded that of ribavirin. Taken together, our results suggest high antiviral activity of DHQ and its promising potential in complex treatment of viral pancreatitis.

Knowles E, Delwart E, Gorbalenya AE, Hovi T, Hyypia T, King AMQ, LinBerg AM, Pallansch MA, Palmenberg AC, Reuter G, Simmonds P, Skern T, Stanway G, Yamashita T, Zell R (2014) Picornaviridae: 26 genera, 46 species and growing, p 98. Abstr. Europic 18th Int. Picornavirus Meet., Blankenberge, Belgium

Blauwet LA, Cooper LT (2010) Myocarditis. Prog Cardiovasc Dis 52:274–288. doi:10.1016/j.pcad.2009.11.006 CrossRefPubMed

Rhoades RE, Tabor-Godwin JM, Tsueng G, Feuer R (2011) Enterovirus infections of the central nervous system. Virology 411:288–305. doi:10.1016/j.virol.2010.12.014 CrossRefPubMedPubMedCentral

Kaprio J, Tuomilehto J, Koskenvuo M, Romanov K, Reunanen A, Eriksson J et al (1992) Concordance for type 1 (insulin dependent) and type 2 (non insulin dependent) diabetes in a population-based cohort of twins in Finland. Diabetologia 35:1060–1067CrossRefPubMed

Kyvik KO, Green A, Beck-Nielsen H (1995) Concordance rates of insulin dependent diabetes mellitus: a population based study of young Danish twins. Br Med J 311:913–917CrossRef

Onkamo P, Vaananen S, Karvonen M, Tuomilehto J (1999) Worldwide increase in incidence of Type 1 diabetes—the analysis of the data on published incidence trends. Diabetologia 42:1395–1403CrossRefPubMed

Todd JA (1999) From genome to aetiology in a multifactorial disease, type 1 diabetes. Bioessays 21:164–174CrossRefPubMed

Yoon JW, Austin M, Onodera T, Notkins AL (1979) Virus-induced diabetes mellitus. N Engl J Med 300:1173–1179CrossRefPubMed

Champsaur HF, Dussaix E, Samolyk D, Fabre M, Bach C, Assan R (1980) Diabetes and Coxsackie virus B5 infection. Lancet i:251CrossRef

10.

Green J, Casabonne D, Newton R (2004) Coxsackie B virus serology and Type 1 diabetes mellitus: a systematic review of published case-control studies. Diabet Med 21:507–514CrossRefPubMed

11.

Stevens T, Conwell DL, Zuccaro G (2004) Pathogenesis of chronic pancreatitis: an evidence-based review of past theories and recent developments. Am J Gastroenterol 99:2256–2270CrossRefPubMed

12.

Gu R, Shampang A, Reilly A, Fisher D, Glass W, Ramsingh AI (2009) IL-10 is pathogenic during the development of coxsackievirus B4-induced chronic pancreatitis. Virology 395:77–86. doi:10.1016/j.virol.2009.09.005 CrossRefPubMedPubMedCentral

13.

Zhu FC, Liang ZL, Li XL, Ge HM, Meng FY, Mao QY, Zhang YT, Hu YM, Zhang ZY, Li JX, Gao F, Chen QH, Zhu QY, Chu K, Wu X, Yao X, Guo HJ, Chen XQ, Liu P, Dong YY, Li FX, Shen XL, Wang JZ (2013) Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 381:1037–1045. doi:10.1016/S0140-6736(12)61764-4 CrossRefPubMed

14.

Shang L, Xu M, Yin Z (2013) Antiviral drug discovery for the treatment of enterovirus 71 infections. Antiviral Res 97:183–194. doi:10.1016/j.antiviral.2012.12.005 CrossRefPubMed

15.

Deng CL, Yeo H, Ye HQ, Liu SQ, Shang BD, Gong P, Alonso S, Shi PY, Zhang B (2014) Inhibition of enterovirus 71 by adenosine analog NITD008. J Virol 88:11915–11923. doi:10.1128/JVI.01207-14 CrossRefPubMedPubMedCentral

16.

Shang L, Wang Y, Qing J, Shu B, Cao L, Lou Z, Gong P, Sun Y, Yin Z (2014) An adenosine nucleoside analogue NITD008 inhibits EV71 proliferation. Antiviral Res 112:47–58. doi:10.1016/j.antiviral.2014.10.009 CrossRefPubMed

17.

Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, Mao N, Xu S, Zhu S, Cui A, Zhang Y, Yan D, Li Q, Dong X, Zhang J, Zhao Y, Wan J, Feng Z, Sun J, Wang S, Li D, Xu W (2010) An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang City of China. Virol J 7:94. doi:10.1186/1743-422X-7-94 CrossRefPubMedPubMedCentral

18.

Dragovich PS, Prins TJ, Zhou R, Johnson TO, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Hou X, Meador JW, Ferre RA, Worland ST (2002) Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7. Structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics. Bioorg Med Chem Lett 12:733–738. doi:10.1016/S0960-894X(02)00008-2 CrossRefPubMed

19.

Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT, Zhou R, Tikhe J, Ford CE, Meador JW, Ferre RA, Brown EL, Binford SL, Brothers MA, DeLisle DM, Worland ST (1999) Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci USA 96:11000–11007. doi:10.1073/pnas.96.20.11000 CrossRefPubMedPubMedCentral

20.

Tijsma A, Franco D, Tucker S, Hilgenfeld R, Froeyen M, Leyssen P, Neyts J (2014) The capsid binder vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. Antimicrob Agents Chemother 58:6990–6992. doi:10.1128/AAC.03328-14 CrossRefPubMedPubMedCentral

21.

De Colibus L, Wang X, Spyrou JA, Kelly J, Ren J, Grimes J, Puerstinger G, Stonehouse N, Walter TS, Hu Z, Wang J, Li X, Peng W, Rowlands DJ, Fry EE, Rao Z, Stuart DI (2014) More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules. Nat Struct Mol Biol 21:282–288. doi:10.1038/nsmb.2769 CrossRefPubMedPubMedCentral

22.

Qing J, Wang Y, Sun Y, Huang J, Yan W, Wang J, Su D, Ni C, Li J, Rao Z, Liu L, Lou Z (2014) Cyclophilin A associates with enterovirus-71 virus capsid and plays an essential role in viral infection as an uncoating regulator. PLoS Pathog 10:e1004422. doi:10.1371/journal.ppat CrossRefPubMedPubMedCentral

23.

Rotbart HA (2002) Treatment of picornavirus infections. Antiviral Res 53:83–98CrossRefPubMed

24.

Tsang SK, Cheh J, Isaacs L, Joseph-McCarthy D, Choi SK, Pevear DC, Whitesides GM, Hogle JM (2001) A structurally biased combinatorial approach for discovering new anti-picornaviral compounds. Chem Biol 8:33–45CrossRefPubMed

25.

Phelps DK, Post CB (1995) A novel basis of capsid stabilization by antiviral compounds. J Mol Biol 254:544–551CrossRefPubMed

26.

Tsang SK, Danthi P, Chow M, Hogle JM (2000) Stabilization of poliovirus by capsid-binding antiviral drugs is due to entropic effects. J Mol Biol 296:335–340CrossRefPubMed

27.

Feil SC, Hamilton S, Krippner GY, Lin B, Luttick A, McConnell DB, Nearn R, Parker MW, Ryan J, Stanislawski PC, Tucker SP, Watson KG, Morton CJ (2012) An orally available 3-ethoxybenzisoxazole capsid binder with clinical activity against human rhinovirus. ACS Med Chem Lett 3:303–307. doi:10.1021/ml2002955 CrossRefPubMedPubMedCentral

28.

Zhang G, Zhou F, Gu B, Ding C, Feng D, Xie F, Wang J, Zhang C, Cao Q, Deng Y, Hu W, Yao K (2012) In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol 157:669–679. doi:10.1007/s00705-011-1222-6 CrossRefPubMed

29.

Fechner H, Pinkert S, Geisler A, Poller W, Kurreck J (2011) Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections. Molecules 16:8475–8503. doi:10.3390/molecules16108475 CrossRefPubMed

30.

FDA: Copegus highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021511s023lbl.pdf

31.

Pietta PG (2000) Flavonoids as antioxidants. J Nat Prod 63:1035–1042CrossRefPubMed

32.

Prasad S, Phromnoi K, Yadav VR, Chaturvedi MM, Aggarwal BB (2010) Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer. Planta Med 76:1044–1063. doi:10.1055/s-0030-1250111 CrossRefPubMed

33.

Chimenti F, Fioravanti R, Bolasco A, Chimenti P, Secci D, Rossi F, Yáñez M, Orallo F, Ortuso F, Alcaro S, Cirilli R, Ferretti R, Sanna ML (2010) A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem 18:1273–1279. doi:10.1016/j.bmc.2009.12.029 CrossRefPubMed

34.

Savov VM, Galabov AS, Tantcheva LP, Mileva MM, Pavlova EL, Stoeva ES, Braykova AA (2006) Effects of rutin and quercetin on monooxygenase activities in experimental influenza virus infection. Exp Toxicol Pathol 58:59–64CrossRefPubMed

35.

Nishizaki Y, Ishimoto Y, Hotta Y, Hosoda A, Yoshikawa H, Akamatsu M, Tamura H (2009) Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett 19:4706–4710. doi:10.1016/j.bmcl.2009.06.073 CrossRefPubMed

36.

Chin YW, Kong JY, Han SY (2013) Flavonoids as receptor tyrosine kinase FLT3 inhibitors. Bioorg Med Chem Lett 23:1768–1770. doi:10.1016/j.bmcl.2013.01.049 CrossRefPubMed

37.

Verghese J, Nguyen T, Oppegard LM, Seivert LM, Hiasa H, Ellis KC (2013) Flavone-based analogues inspired by the natural product simocyclinone D8 as DNA gyrase inhibitors. Bioorg Med Chem Lett 23:5874–5877. doi:10.1016/j.bmcl.2013.08.094 CrossRefPubMed

38.

Kumar P, Kushwaha P, Khedgikar V, Gautam J, Choudhary D, Singh D, Trivedi R, Maurya R (2014) Neoflavonoids as potential osteogenic agents from Dalbergia sissoo heartwood. Bioorg Med Chem Lett 24:2664–2668. doi:10.1016/j.bmcl.2014.04.056 CrossRefPubMed

39.

Liu AL, Wang HD, Lee SM, Wang YT, Du GH (2008) Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities. Bioorg Med Chem 16:7141–7147. doi:10.1016/j.bmc.2008.06.049 CrossRefPubMed

40.

Abdal Dayem A, Choi HY, Kim YB, Cho SG (2015) Antiviral effect of methylated flavonol isorhamnetin against influenza. PLoS One 10:e0121610CrossRefPubMed

41.

Wang J, Zhang T, Du J, Cui S, Yang F, Jin Q (2014) Anti-enterovirus 71 effects of chrysin and its phosphate ester. PLoS One 9(3):e89668CrossRefPubMedPubMedCentral

42.

Senthilvel P, Lavanya P, Kumar KM, Swetha R, Anitha P, Bag S, Sarveswari S, Vijayakumar V, Ramaiah S, Anbarasu A (2013) Flavonoid from Carica papaya inhibits NS2B-NS3 protease and prevents Dengue 2 viral assembly. Bioinformation 9(18):889–895. doi:10.6026/97320630009889 CrossRefPubMedPubMedCentral

43.

Galochkina AV, Zarubaev VV, Kiselev OI, Babkin VA, Ostrouhova LA (2015) Study of anti-viral activity of dihydroquercetin in the course of replication of Coxsackievirus B4 in vitro. Voprosy virusologii (in press)

44.

Zenkevich IG, Eshenko AY, Makarov VG, Kolesnik YA, Shmatkov DA, Tikhonov VP (2006) Optical pure isomers of dihydroquercetin. Composition of Bioflavonoid Complex of Larix: Stereoisomerism of Dihydroquercetin. The X international congress PHYTOPHARM. Actual problems of creation of new medical preparations of natural origin, St. Petersburg 93–109

45.

Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659–661CrossRefPubMed

46.

Brand-Williams W, Cuvelier ME, Berset C (1995) Use of a free radical method to evaluate antioxidant activity. Lebenson Wiss Technol 28:25–30CrossRef

47.

de Moura CF, Noguti J, de Jesus GP, Ribeiro FA, Garcia FA, Gollucke AP, Aguiar O Jr, Ribeiro DA (2013) Polyphenols as a chemopreventive agent in oral carcinogenesis: putative mechanisms of action using in-vitro and in-vivo test systems. Eur J Cancer Prev 22:467–472. doi:10.1097/CEJ.0b013e32835b6a94 CrossRefPubMed

48.

Giovannini C, Masella R (2012) Role of polyphenols in cell death control. Nutr Neurosci 15:134–149. doi:10.1179/1476830512Y.0000000006 CrossRefPubMed

49.

Wang HQ, Meng S, Li ZR, Peng ZG, Han YX, Guo SS, Cui XL, Li YH, Jiang JD (2013) The antiviral effect of 7-hydroxyisoflavone against Enterovirus 71 in vitro. J Asian Nat Prod Res 15:382–389. doi:10.1080/10286020.2013.770737 CrossRefPubMed

50.

Panchal RG, Reid SP, Tran JP, Bergeron AA, Wells J, Kota KP, Aman J, Bavari S (2012) Identification of an antioxidant small-molecule with broad-spectrum antiviral activity. Antiviral Res 93:23–29. doi:10.1016/j.antiviral.2011.10.011 CrossRefPubMed

51.

Nathan C, Cunningham-Bussel A (2013) Beyond oxidative stress: an immunologist’s guide to reactive oxygen species. Nat Rev Immunol 13:349–361. doi:10.1038/nri3423 CrossRefPubMedPubMedCentral

52.

Vasallo C, Gastaminza P (2015) Cellular stress responses in hepatitis C virus infection: Mastering a two-edged sword. Virus Res 209:100–117. doi:10.1016/j.virusres.2015.03.013 CrossRefPubMed

53.

Domej W, Oettl K, Renner W (2014) Oxidative stress and free radicals in COPD–implications and relevance for treatment. Int J Chron Obstruct Pulmon Dis 9:1207–1224. doi:10.2147/COPD.S5122 CrossRefPubMedPubMedCentral

54.

Reshi ML, Su YC, Hong JR (2014) RNA viruses: ROS-mediated cell death. Int J Cell Biol. doi:10.1155/2014/467452 PubMedPubMedCentral

55.

Garofalo RP, Kolli D, Casola A (2013) Respiratory syncytial virus infection: mechanisms of redox control and novel therapeutic opportunities. Antioxid Redox Signal 18:186–217. doi:10.1089/ars.2011.4307 CrossRefPubMedPubMedCentral

56.

Peterhans E (1997) Oxidants and antioxidants in viral diseases: disease mechanisms and metabolic regulation. J Nutr 127(5 Suppl):962S–965SPubMed

57.

Schwarz KB (1996) Oxidative stress during viral infection: a review. Free Radic Biol Med 21:641–649CrossRefPubMed

58.

Rakers C, Schwerdtfeger SM, Mortier J, Duwe S, Wolff T, Wolber G, Melzig MF (2014) Inhibitory potency of flavonoid derivatives on influenza virus neuraminidase. Bioorg Med Chem Lett 24:4312–4317. doi:10.1016/j.bmcl.2014.07.010 CrossRefPubMed

59.

Sithisarn P, Michaelis M, Schubert-Zsilavecz M, Cinatl J Jr (2013) Differential antiviral and anti-inflammatory mechanisms of the flavonoids biochanin A and baicalein in H5N1 influenza A virus-infected cells. Antiviral Res 97:41–48. doi:10.1016/j.antiviral.2012.10.004 CrossRefPubMed

60.

Ho HY, Cheng ML, Weng SF, Chang L, Yeh TT, Shih SR, Chiu DT (2008) Glucose-6-phosphate dehydrogenase deficiency enhances enterovirus 71 infection. J Gen Virol 89:2080–2089. doi:10.1099/vir.0.2008/001404-0 CrossRefPubMed

61.

Ho HY, Cheng ML, Weng SF, Leu YL, Chiu DT (2009) Antiviral effect of epigallocatechin gallate on enterovirus 71. J Agric Food Chem 57:6140–6147. doi:10.1021/jf901128u CrossRefPubMed

62.

Kalebic T, Kinter A, Poli G, Anderson ME, Meister A, Fauci AS (1991) Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine. Proc Natl Acad Sci USA 88:986–990CrossRefPubMedPubMedCentral

63.

Ghezzi P, Ungheri D (2004) Synergistic combination of N-acetylcysteine and ribavirin to protect from lethal influenza viral infection in a mouse model. Int J Immunopathol Pharmacol 17:99–102PubMed

64.

Garozzo A, Tempera G, Ungheri D, Timpanaro R, Castro A (2007) N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection. Int J Immunopathol Pharmacol 20:349–354PubMed

65.

Si X, McManus BM, Zhang J, Yuan J, Cheung C, Esfandiarei M, Suarez A, Morgan A, Luo H (2005) Pyrrolidine dithiocarbamate reduces coxsackievirus B3 replication through inhibition of the ubiquitin-proteasome pathway. J Virol 79:8014–8023CrossRefPubMedPubMedCentral

66.

Tsai K, Wang SS, Chen TS, Kong CW, Chang FY, Lee SD, Lu FJ (1998) Oxidative stress: an important phenomenon with pathogenetic significance in the progression of acute pancreatitis. Gut 42:850–855CrossRefPubMedPubMedCentral

67.

Schulz HU, Niederau C, Klonowski-Stumpe H, Halangk W, Luthen R, Lippert H (1999) Oxidative stress in acute pancreatitis. Hepatogastroenterology 46:2736–2750PubMed

68.

Telek G, Ducro R, Scoazec JY, Pasquier C, Feldmann G, Roze C (2001) Differential upregulation of cellular adhesion molecules at the sites of oxidative stress in experimental acute pancreatitis. J Surg Res 96:56–67CrossRefPubMed

69.

Telek G, Regoly-Merei J, Kovacs GC, Simon L, Nagy Z, Hamar J, Jakab F (2001) The first histological demonstration of pancreatic oxidative stress in human acute pancreatitis. Hepatogastroenterology 48:1252–1258PubMed

70.

Sanfey H, Bulkley GB, Cameron JL (1984) The role of oxygen-derived free radicals in the pathogenesis of acute pancreatitis. Ann Surg 200:405–413CrossRefPubMedPubMedCentral

71.

Guice KS, Miller DE, Oldham KT, Townsend CM Jr, Thompson JC (1986) Superoxide dismutase and catalase: a possible role in established pancreatitis. Am J Surg 151:163–169CrossRefPubMed

72.

Schoenberg MH, Buchler M, Beger HG (1992) The role of oxygen radicals in experimental acute pancreatitis. Free Radic Biol Med 12:515–522CrossRefPubMed

73.

Sweiry JH, Mann GE (1996) Role of oxidative stress in the pathogenesis of acute pancreatitis. Scand J Gastroenterol Suppl 219:10–15CrossRefPubMed

74.

Rau B, Bauer A, Wang A, Gansauge F, Weidenbach H, Nevalainen T, Poch B, Beger HG, Nussler AK (2001) Modulation of endogenous nitric oxide synthase in experimental acute pancreatitis: role of anti-ICAM-1 and oxygen free radical scavengers. Ann Surg 233:195–203CrossRefPubMedPubMedCentral

75.

Lee JH, An CS, Yun BS, Kang KS, Lee YA, Won SM, Gwag BJ, Cho SI, Hahm KB (2012) Prevention effects of ND-07, a novel drug candidate with a potent antioxidative action and anti-inflammatory action, in animal models of severe acute pancreatitis. Eur J Pharmacol 687:28–38. doi:10.1016/j.ejphar.2012.04.048 CrossRefPubMed

76.

Robertson RP, Harmon JS (2007) Pancreatic islet beta-cell and oxidative stress: the importance of glutathione peroxidase. FEBS Lett 581:3743–3748CrossRefPubMedPubMedCentral

Title: Virus-inhibiting activity of dihydroquercetin, a flavonoid from Larix sibirica, against coxsackievirus B4 in a model of viral pancreatitis
Authors: Anastasia V. Galochkina
Vadim B. Anikin
Vasily A. Babkin
Liudmila A. Ostrouhova
Vladimir V. Zarubaev
Publication date: 01-04-2016
Publisher: Springer Vienna
Published in: Archives of Virology / Issue 4/2016
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-016-2749-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2016

Molecular characterization of a novel capillovirus from red currant

Comparison of beak and feather disease virus prevalence and immunity-associated genetic diversity over time in an island population of red-crowned parakeets

Detection and genetic characterization of a novel parvovirus distantly related to human bufavirus in domestic pigs

Detection of bovine leukemia virus and identification of its genotype in Mongolian cattle

Complete genome sequence of tobacco virus 1, a closterovirus from Nicotiana tabacum

Sequence analysis and evaluation of the NS3/A gene region of bluetongue virus isolates from South Africa

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage